Ketamine: From Prescription Anaesthetic to a New Psychoactive Substance

Maria   Rosaria   Varì; Giovanna      Ricci; Marco      Cavallo; Simona      Pichini; Ascanio      Sirignano; Silvia      Graziano

doi:10.2174/1381612828666220510115209

Abstract

Discovered in the United States of America (USA) in the 1960s, ketamine was introduced as an anaesthetic drug to specifically replace phencyclidine. Briefly, the substance moved from the medical world to recreational users, since it was discovered that intense psychedelic experiences were obtained with dosages lower than those prescribed for anesthesia. At the end of the 90’s, it was circulated in London nightclubs as a drug itself and as counterfeit 3,4-methylenedioxymethamphetamine tablets. In 1997, the Drug Enforcement Administration (DEA) alerted the United States (US) government about the increasing diffusion of ketamine in American 'clubs', and in 1999, the substance was added to Schedule III of drugs controlled by federal authorities. In 2002, ketamine epidemics moved to Europe, and the European Monitoring Centre for Drugs and Drug Addiction carried out a risk assessment monitoring of the phenomenon. An estimated ninety-nine percent of all global ketamine seizures occurred in Asia. Its growing popularity is due to the fact that this new psychoactive substance is cheaper than other stimulants, such as MDMA. Moreover, the amount used for recreational purposes does not cause respiratory depression and its legal use as a drug makes it widely available for a diversion towards illicit markets. Nevertheless, acute intoxication and several deaths have been related to exclusive ketamine use both in Europe and internationally. Since 2015, there has been an increasing rise in the illicit ketamine market, and currently, the drug is being used with unprecedented peaks and a consequent significant increase in seizures and clinical cases worldwide.

Keywords: Ketamine, arylcycloalkylamine, anaesthetic, dissociative, new psychoactive substance, psychedelic.

« Previous Next »

[1] 
Domino EF. Taming the ketamine tiger. 1965. Anesthesiology  2010; 113(3): 678-84.
[http://dx.doi.org/10.1097/ALN.0b013e3181ed09a2] [PMID:  20693870] 
[2] 
McCarthy DA, Chen G, Kaump DH, Ensor C. General anesthetic and other pharmacological properties of 2- (O-chlorophenyl)-2-methylamino cyclohexanone HCl (CI 581). J New Drugs  1965; 5(1): 21-33.
[http://dx.doi.org/10.1002/j.1552-4604.1965.tb00219.x] [PMID:  14283065] 
[3] 
Trujillo KA, Smith ML, Sullivan B, Heller CY, Garcia C, Bates M. The neurobehavioral pharmacology of ketamine: Implications for drug abuse, addiction, and psychiatric disorders. Lab Animal Res J  2011; 52(3): 366-78.
[http://dx.doi.org/10.1093/ilar.52.3.366] [PMID:  23382150] 
[4] 
Rogers J. Ketamine and Kalashnikovs . Personal views. BMJ 1997;
  315: 1473-9.. 
[http://dx.doi.org/10.1136/bmj.315.7120.1473.] 
[5] 
de Rocquigny G, Dubecq C, Martinez T, et al. Use of ketamine for prehospital pain control on the battlefield: A systematic review. J Trauma Acute Care Surg  2020; 88(1): 180-5.
[http://dx.doi.org/10.1097/TA.0000000000002522] [PMID:  31688832] 
[6] 
Worrell SD, Gould TJ. Therapeutic potential of ketamine for alcohol use disorder. Neurosci Biobehav Rev  2021; 126: 573-89.
[http://dx.doi.org/10.1016/j.neubiorev.2021.05.006] [PMID:  33989669] 
[7] 
Dean RL, Hurducas C, Hawton K, et al. Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder. Cochrane Database Syst Rev  2021; 9, CD011612.
[PMID:  34510411] 
[8] 
Swainson J, McGirr A, Blier P, et al. The Canadian Network for mood and Anxiety Treatments (CANMAT) task force recommendations for the use of racemic ketamine in adults with major depressive disorder: Recommandations Du Groupe De Travail Du Réseau Canadien Pour Les Traitements De L’humeur Et De L’anxiété (Canmat) Concernant L’utilisation De La Kétamine Racémique Chez Les Adultes Souffrant De Trouble Dépressif Majeur. Can J Psychiatry  2021; 66(2): 113-25.
[http://dx.doi.org/10.1177/0706743720970860] [PMID:  33174760] 
[9] 
Chen MH, Lin WC, Wu HJ, et al. Efficacy of low-dose ketamine infusion in anxious vs nonanxious depression: Revisiting the adjunctive ketamine study of taiwanese patients with treatment-resistant depression. CNS Spectr  2021; 26(4): 362-7.
[http://dx.doi.org/10.1017/S1092852920001194] [PMID:  32419678] 
[10] 
Suarez S, Burke TF, Yusufali T, Makin J, Sessler DI. The role of ketamine in addressing the anesthesia gap in low-resource settings. J Clin Anesth  2018; 49: 42-3.
[http://dx.doi.org/10.1016/j.jclinane.2018.06.009] [PMID:  29885624] 
[11] 
Total synthesis of ketamine. Zealot: [update 2005 May; cites 2004 August]. Available from: . https://erowid.org/archive/rhodium/chemistry/ketamine 2.html
[12] 
Zekri N, Fareghi-Alamdari R, Momeni-Fard B. Synthesis of ketamine from a nontoxic procedure: A new and efficient route. J Chem Sci  2020; 132: 134.
[http://dx.doi.org/10.1007/s12039-020-01827-9] 
[13] 
Siegel RK. Phencyclidine and ketamine intoxication: A study of four populations of recreational users. NIDA Res Monogr  1978; 21(21): 119-47.
[PMID:  101865] 
[14] 
United Nations Office on Drug Control (UNODC). World Drug Report 2010. Available from:
          https://www.unodc.org/documents/wdr/WDR_2010/W orld_Drug_Report_2010_lo-res.pdf
[15] 
Moore M, Alltounian HS, Eds. Journeys Into the Bright World. Rockport: Para Research 1978.
[16] 
Lilly JC, Ed. The Scientist A Metaphysical Autobiography. Berkeley: Roning Publishing 1988.
[17] 
Wolff K, Winstock AR. Ketamine: From medicine to misuse. CNS Drugs  2006; 20(3): 199-218.
[http://dx.doi.org/10.2165/00023210-200620030-00003] [PMID:  16529526] 
[18] 
Walker-Journey J. What are K-Holes? The ketamine experience explained 2021. Available from:. https://psychedelicspotlight.com/what-are-k-holes/
[19] 
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). . Report on the risk assessment of ketamine in the framework of the joint action on new synthetic drugs 2002.  Available from: 
          https://www.emcdda.europa.eu/system/files/publication s/173/Risk3_62941.pdf
[20] 
Smith KM. Drugs used in acquaintance rape. J Am Pharm Assoc  1999; 39(4): 519-25.
[http://dx.doi.org/10.1016/S1086-5802(16)30472-7] [PMID:  10467817] 
[21] 
Graeme KA. New drugs of abuse. Emerg Med Clin North Am  2000; 18(4): 625-36.
[http://dx.doi.org/10.1016/S0733-8627(05)70150-4] [PMID:  11130930] 
[22] 
Morgan CJ, Curran HV. Ketamine use: A review. Addiction  2012; 107(1): 27-38.
[http://dx.doi.org/10.1111/j.1360-0443.2011.03576.x] [PMID:  21777321] 
[23] 
Li JH, Vicknasingam B, Cheung YW, et al. To use or not to use: An update on licit and illicit ketamine use. Subst Abuse Rehabil  2011; 2: 11-20.
[http://dx.doi.org/10.2147/SAR.S15458] [PMID:  24474851] 
[24] 
Rica  Costa , de Salud . Ministerio. Comunicado de prensa, Press Release.. 2015.
[25] 
Rica  Costa, Ministerio de Seguridad Pública. Policía de Fronteras decomisa millonario cargamento de ketamina a prófuga de la Justicia de Costa Rica y Nicaragua Press Release  2017.
[26] 
Observatorio del narcotráfico – Informe. Chile: Ministerio Publico  de Chile Fiscalía. 2020.
[27] 
 United Nations Office on Drugs and Crime (UNODC) synthetic
  drugs and new psychoactive substances in Latin America and the
  Caribbean. . 2021.
[28] 
 Thirtieth Meeting of Heads of National Law Enforcement Agencies, Africa (HONLAF) UNODC/HONLAF/30/2 , . 2020.
[29] 
Report of the International Narcotics Control Board for 2018  (United Nations publication, Sales No. E.19.XI.2). 2018.. 
[30] 
Ni A, Lee Cantrell F, Clark RF. Ketamine exposure demographics and outcomes over 16 years as reported to US poison centers. Am J Emerg Med  2018; 36(8): 1459-62.
[http://dx.doi.org/10.1016/j.ajem.2018.04.066] [PMID:  29754964] 
[31] 
European Monitoring Centre for Drugs and Drug Addiction
  (EMCDDA). European Drug Report 2018: Trends and Developments
  2018. Available from: . https://www.emcdda.europa.eu/system/files/publication s/8585/20181816_TDAT18001ENN_PDF.pdf
[32] 
European Monitoring Centre for Drugs and Drug Addiction
  (EMCDDA). European Drug Report 2019: Trends and Developments
  2019. Available from: . https://www.emcdda.europa.eu/system/files/publication s/11364/20191724_TDAT19001ENN_PDF.pdf
[33] 
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). European Drug Report 2020: Trends and Developments. 2020. Available from: . https://www.emcdda.europa.eu/system/files/publication s/13236/TDAT20001ENN_web.pdf
[34] 
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). European Drug Report 2021.  Available from:
          https://www.emcdda.europa.eu/system/files/publication s/13838/TDAT21001ENN.pdf
[35] 
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Statistical Bulletin 2021. Available from:
          https://www.emcdda.europa.eu/data/stats2021/szr_en
[36] 
Kalsi SS, Wood DM, Dargan PI. The epidemiology and patterns of acute and chronic toxicity associated with recreational ketamine use. Emerg Health Threats J  2011; 4: 7107.
[http://dx.doi.org/10.3402/ehtj.v4i0.7107] [PMID:  24149025] 
[37] 
Arditti J. Ketamine, déviation d’usage en France. Marseille, France: CEIP 2000.
[38] 
Felser JM, Orban DJ. Dystonic reaction after ketamine abuse. Ann Emerg Med  1982; 11(12): 673-5.
[http://dx.doi.org/10.1016/S0196-0644(82)80263-1] [PMID:  7149360] 
[39] 
Tang J, Liao Y, He H, et al. Sleeping problems in Chinese illicit drug dependent subjects. BMC Psychiatry  2015; 15(1): 1-7.
[http://dx.doi.org/10.1186/s12888-015-0409-x] [PMID:  25884573] 
[40] 
Tang M, Ching CK, Tse ML, et al. Surveillance of emerging drugs of abuse in Hong Kong: Validation of an analytical tool. Hong Kong Med J  2015; 21(2): 114-23.
[http://dx.doi.org/10.12809/hkmj144398] [PMID:  25756277] 
[41] 
Jia Z, Liu Z, Chu P, et al. Tracking the evolution of drug abuse in China, 2003-10: A retrospective, self-controlled study. Addiction  2015; 110(Suppl. 1): 4-10.
[http://dx.doi.org/10.1111/add.12769] [PMID:  25533859] 
[42] 
Lian Z, Liu Z, Liu R, et al. Epidemiological survey of ketamine in China. Chin J Drug Depend  2005; 14: 280-3.
[43] 
Pavarin RM, Marani S, Turino E. Ketamine abusers referring to emergency departments in northern Italy: A cross- sectional study. Ann Ist Super Sanita  2019; 55(4): 338-44.
[PMID:  31850860] 
[44] 
Papa P, Valli A, Di Tuccio M, et al. Prevalence of stimulant, hallucinogen, and dissociative substances detected in biological samples of NPS-intoxicated patients in Italy. J Psychoactive Drugs  2021; 53(3): 247-55.
[http://dx.doi.org/10.1080/02791072.2020.1862370] [PMID:  33470904] 
[45] 
Graziano S, Zaami S, Tittarelli R, et al. The complex and constantly evolving public health threat of new psychoactive substances in Italy: Addressing the main functions of a national observatory of drugs. Ann Ist Super Sanita  2021; 57(2): 144-50.
[PMID:  34132212] 
[46] 
Varì MR, Zaami S, Pacifici R, et al. Sistema Nazionale di Allerta Precoce, una piattaforma web per il contrasto alla diffusione delle Nuove Sostanze Psicoattive. Biochim Clin  2021; 45: 267-80.
[47] 
Liao Y, Tang J, Corlett PR, et al. Reduced dorsal prefrontal gray matter after chronic ketamine use. Biol Psychiatry  2011; 69(1): 42-8.
[http://dx.doi.org/10.1016/j.biopsych.2010.08.030] [PMID:  21035788] 
[48] 
Morgan CJ, Muetzelfeldt L, Curran HV. Consequences of chronic ketamine self-administration upon neurocognitive function and psychological wellbeing: A 1-year longitudinal study. Addiction  2010; 105(1): 121-33.
[http://dx.doi.org/10.1111/j.1360-0443.2009.02761.x] [PMID:  19919593] 
[49] 
Tang WK, Morgan CJ, Lau GC, Liang HJ, Tang A, Ungvari GS. Psychiatric morbidity in ketamine users attending counselling and youth outreach services. Subst Abus  2015; 36(1): 67-74.
[http://dx.doi.org/10.1080/08897077.2014.935560] [PMID:  25023206] 
[50] 
Berman RM, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry  2000; 47(4): 351-4.
[http://dx.doi.org/10.1016/S0006-3223(99)00230-9] [PMID:  10686270] 
[51] 
Gill JR, Stajíc M. Ketamine in non-hospital and hospital deaths in New York city. J Forensic Sci  2000; 45(3): 655-8.
[http://dx.doi.org/10.1520/JFS14742J] [PMID:  10855972] 
[52] 
Li F, Liu J, Yip PSF, Lu X, Liu S. Mortalities of methamphetamine, opioid, and ketamine abusers in Shanghai and Wuhan, China. Forensic Sci Int  2020; 306, 110093.
[http://dx.doi.org/10.1016/j.forsciint.2019.110093] [PMID:  31816483] 
[53] 
Darke S, Duflou J, Farrell M, Peacock A, Lappin J. Characteristics and circumstances of death related to the self-administration of ketamine. Addiction  2021; 116(2): 339-45.
[http://dx.doi.org/10.1111/add.15154] [PMID:  32533718] 
[54] 
Schifano F, Corkery J, Oyefeso A, Tonia T, Ghodse AH. Trapped in the “K-hole”: Overview of deaths associated with ketamine misuse in the UK (1993-2006). J Clin Psychopharmacol  2008; 28(1): 114-6.
[http://dx.doi.org/10.1097/JCP.0b013e3181612cdc] [PMID:  18204359] 
[55] 
Corkery JM, Hung WC, Claridge H, Goodair C, Copeland CS, Schifano F. Recreational ketamine-related deaths notified to the national programme on substance abuse deaths, England, 1997-2019. J Psychopharmacol  2021; 35(11): 1324-48.
[http://dx.doi.org/10.1177/02698811211021588] [PMID:  34092131] 
[56] 
Shaw KP, Chiu CC, Chung FC, et al. Illicit drugs surveillance system and ketamine-related fatalities in Taiwan, 2001-2008. Annual meeting of the American Academy of Forensic Sciences. Seattle, Washington. 2010.
[57] 
Lalonde BR, Wallage HR. Postmortem blood ketamine distribution in two fatalities. J Anal Toxicol  2004; 28(1): 71-4.
[http://dx.doi.org/10.1093/jat/28.1.71] [PMID:  14987429] 
[58] 
Centini F, Gabbrielli M, Fineshi V, et al. Fatal ketamine abuse: report of a case and analytical determination by gas liquid chromatography, mass spectrometry.In: Piemonte G, Tagliaro F, Marigo. M, Frigerio A, Eds Developments in analytical methods in pharmaceutical, biomedical, and Forensic Sciences.  New York: Plenum Press Co 1987; pp. 147-53.
[http://dx.doi.org/10.1007/978-1-4899-3526-7_17] 
[59] 
Licata M, Pierini G, Popoli G. A fatal ketamine poisoning. J Forensic Sci  1994; 39(5): 1314-20.
[http://dx.doi.org/10.1520/JFS13718J] [PMID:  7964568] 
[60] 
dell’Interno M. Dipartimento della Pubblica Sicurezza – Direzione Centrale per i Servizi Antidroga (DCSA). Relazione annuale 2021.
  2021. Available from: . https://antidroga.interno.gov.it/wp- content/uploads/2021/07/Relazione-Annuale-2021.pdf
[61] 
Schatzberg AF. A word to the wise about ketamine. Am J Psychiatry  2014; 171(3): 262-4.
[http://dx.doi.org/10.1176/appi.ajp.2014.13101434] [PMID:  24585328] 
[62] 
Breen C, Degenhardt L, White B, et al. Australian Party Drugs Trends 2003. Available from: 
          https://ndarc.med.unsw.edu.au/sites/default/files/ndarc/resources/Mono.52.pdf
[63] 
Lee KH, Yeh YC, Yang PC, et al. Individual and peer factors associated with ketamine use among adolescents in Taiwan. Eur Child Adolesc Psychiatry  2012; 21(10): 553-8.
[http://dx.doi.org/10.1007/s00787-012-0292-7] [PMID:  22722663] 
[64] 
Liao Y, Tang YL, Hao W. Ketamine and international regulations. Am J Drug Alcohol Abuse  2017; 43(5): 495-504.
[http://dx.doi.org/10.1080/00952990.2016.1278449] [PMID:  28635347] 
[65] 
 World Health Organization. Ketamine - Expert peer review on
  critical review report (1). 35th Expert Committee on Drug Dependence.
  Hammamet, Tunisia. June 4-8, 2012; pp. 1-5.. 
[66] 
 Home Office. The misuse of drugs (amendment) (No. 3) regulations
  2005. SI 2005 No. 3372 Dangerous Drugs 2005. Available
  from: . https://www.legislation.gov.uk/uksi/2005/3372/pdfs/uk siem_20053372_en.pdf
[67] 
McCambridge J, Winstock A, Hunt N, Mitcheson L. 5-Year trends in use of hallucinogens and other adjunct drugs among UK dance drug users. Eur Addict Res  2007; 13(1): 57-64.
[http://dx.doi.org/10.1159/000095816] [PMID:  17172780] 
[68] 
Smith K, Flatley J. Drug Misuse Declared: Findings from the
  2010/11 British Crime Survey. England and Wales (HOSB: 12/11)
  2011. Available from: . https://assets.publishing.service.gov.uk/government/upl oads/system/uploads/attachment_data/file/116333/hosb 1211.pdf
[69] 
World Health Organization; WHO Expert Committee on Drug Dependence  Thirty-fourth Report. 2006. Available from:. https://apps.who.int/iris/bitstream/handle/10665/43608/9789241209427_eng.pdf
[70] 
World Health Organization; WHO Expert Committee on Drug Dependence . Thirty-fifth Report. 2012. Available from:. https://apps.who.int/iris/bitstream/handle/10665/77747/WHO_trs_973_eng.pdf
[71] 
CAM; Coordination Centre Assessment and Monitoring of new drugsIn: The Hague: Risicoschattingsreport betreffende ketamine.  2001.
[72] 
E/CN.7/2015/7. Commission on Narcotics Drugs, Changes in the
  scope of control of substances. Note by the Secretariat 15. Available
  from:. http://www.unodc.org/documents/commissions/CND/Mandate_and_Functions/E-CN7-2015-7.pdf
[73] 
 E/CN.7/2015/15, Commission on Narcotic Drugs, Report
  on the fifty-eight session (5 December 2014 and 9-17 march
  2015), pp. 69.. 
[74] 
Zaami S. New psychoactive substances: Concerted efforts and common legislative answers for stemming a growing health hazard. Eur Rev Med Pharmacol Sci  2019; 23(22): 9681-90.
[PMID:  31799633] 
[75] 
Marchei E, Pacifici R, Mannocchi G, et al. New synthetic opioids in biological and non-biological matrices: A review of current analytical methods. Trends Analyt Chem  2018; 102: 1-15.
[http://dx.doi.org/10.1016/j.trac.2018.01.007] 
[76] 
Malaca S, Carlier J, Busardò FP. Advances in Forensic Toxicology. Curr Pharm Des  2020; 26(31): 3779-80.
[http://dx.doi.org/10.2174/138161282631200810123637] [PMID:  32942971] 
[77] 
Zaami S, Busardò FP, Pichini S, Pacifici R, Marinelli E. The value of toxicological and forensic analyses in the global challenge to health risks caused by new psychoactive substances. Eur Rev Med Pharmacol Sci  2019; 23(14): 6008-10.
[PMID:  31364102] 
[78] 
Graziano S, Anzillotti L, Mannocchi G, Pichini S, Busardò FP. Screening methods for rapid determination of new psychoactive substances (NPS) in conventional and non-conventional biological matrices. J Pharm Biomed Anal  2019; 163: 170-9.
[http://dx.doi.org/10.1016/j.jpba.2018.10.011] [PMID:  30316062] 
[79] 
Odoardi S, Fisichella M, Romolo FS, Strano-Rossi S. High-throughput screening for new psychoactive substances (NPS) in whole blood by DLLME extraction and UHPLC-MS/MS analysis. J Chromatogr B Analyt Technol Biomed Life Sci  2015; 1000: 57-68.
[http://dx.doi.org/10.1016/j.jchromb.2015.07.007] [PMID:  26209771] 
[80] 
Trana AD, Mannocchi G, Pirani F, et al. a comprehensive hplc-ms-ms screening method for 77 new psychoactive substances, 24 classic drugs and 18 related metabolites in blood, urine and oral fluid. J Anal Toxicol  2020; 44(8): 769-83.
[http://dx.doi.org/10.1093/jat/bkaa103] [PMID:  32816015] 
[81] 
Mannocchi G, Di Trana A, Tini A, et al. Development and validation of fast UHPLC-MS/MS screening method for 87 NPS and 32 other drugs of abuse in hair and nails: Application to real cases. Anal Bioanal Chem  2020; 412(21): 5125-45.
[http://dx.doi.org/10.1007/s00216-020-02462-6] [PMID:  32062830] 
[82] 
Favretto D, Vogliardi S, Stocchero G, et al. Determination of ketamine and norketamine in hair by micropulverized extraction and liquid chromatography-high resolution mass spectrometry. Forensic Sci Int  2013; 226(1-3): 88-93.
[http://dx.doi.org/10.1016/j.forsciint.2012.12.013] [PMID:  23332811] 
[83] 
Lee VW, Cheng JY, Cheung ST, et al. The first international proficiency test on ketamine and norketamine in hair. Forensic Sci Int  2012; 219: 272-7.
[84] 
So PK, Ng TT, Wang H, Hu B, Yao ZP. Rapid detection and quantitation of ketamine and norketamine in urine and oral fluid by wooden-tip electrospray ionization mass spectrometry. Analyst (Lond)  2013; 138(8): 2239-43.
[http://dx.doi.org/10.1039/c3an36641c] [PMID:  23334728] 
[85] 
Albright JA, Stevens SA, Beussman DJ. Detecting ketamine in beverage residues: Application in date rape detection. Drug Test Anal  2012; 4(5): 337-41.
[http://dx.doi.org/10.1002/dta.335] [PMID:  22114065] 
[86] 
Pallavi D, Sudhir KS, Kailash CG. Modified Scott’s test for ketamine hydrochloride. Aust J Forensic Sci  2013; 45: 165-71.
[http://dx.doi.org/10.1080/00450618.2012.733026] 
[87] 
Kim EM, Lee JS, Choi SK, Lim MA, Chung HS. Analysis of ketamine and norketamine in urine by automatic solid-phase extraction (SPE) and positive ion chemical ionization-gas chromatography-mass spectrometry (PCI-GC-MS). Forensic Sci Int  2008; 174(2-3): 197-202.
[http://dx.doi.org/10.1016/j.forsciint.2007.04.217] [PMID:  17553643] 
[88] 
 Mandelin EZ Testing Kit. EZ Test. Available from:. http://www.eztestkits.com/en/mandelin-ez-testing-kit
[89] 
Bertol E, Bigagli L, D’Errico S, et al. Analysis of illicit drugs seized in the Province of Florence from 2006 to 2016. Forensic Sci Int  2018; 284: 194-203.
[http://dx.doi.org/10.1016/j.forsciint.2018.01.010] [PMID:  29408729] 
[90] 
Schram J, Parrilla M, Sleegers N, et al. Identifying electrochemical fingerprints of ketamine with voltammetry and liquid chromatography-mass spectrometry for its detection in seized samples. Anal Chem  2020; 92(19): 13485-92.
[http://dx.doi.org/10.1021/acs.analchem.0c02810] [PMID:  32786496] 
[91] 
Liu CM, Han Y, Min SG, Jia W, Meng X, Liu PP. Rapid qualitative and quantitative analysis of methamphetamine, ketamine, heroin, and cocaine by near-infrared spectroscopy. Forensic Sci Int  2018; 290: 162-8.
[http://dx.doi.org/10.1016/j.forsciint.2018.07.008] [PMID:  30053735] 
[92] 
Schmid MG, Hägele JS. Separation of enantiomers and positional isomers of novel psychoactive substances in solid samples by chromatographic and electrophoretic techniques - A selective review. J Chromatogr A  2020; 1624, 461256.
[http://dx.doi.org/10.1016/j.chroma.2020.461256] [PMID:  32540082] 

Rights & Permissions Print Cite

Article Metrics

27

1

Journal Information

For Authors

For Editors

For Reviewers

Explore Articles

Open Access

Open Access Articles

For Visitors

DOI https://dx.doi.org/10.2174/1381612828666220510115209	Print ISSN 1381-6128
Publisher Name Bentham Science Publisher	Online ISSN 1873-4286

Current Pharmaceutical Design

Ketamine: From Prescription Anaesthetic to a New Psychoactive Substance

Abstract Play Pause

Related Journals

Related Books

Abstract